trial · primary record
Daunorubicin/Idarubicin
AML, Adult
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 228 |
| Primary completion | 2028-08-30 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT07132684 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:50.256Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07132684
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.